Role of ganaton in antiemetic therapy. New treatment capacities
https://doi.org/10.17650/1994-4098-2010-0-4-49-53
Abstract
The practical introduction of new effective drugs for the prevention and treatment of nausea and vomiting is one of the important constitu- ents of maintenance therapy in cancer patients, which helps maintain a good quality of life during drug treatment. This paper considers the main mechanisms of occurrence of nausea and vomiting and current recommendations for their prevention and gives the results of the authors’ studies evaluating the use of ganaton, a D2-receptor antagonist, alone and in combination with 5-HT3-receptor antagonists for the prevention and treatment of acute and delayed nausea and vomiting. The drug has shown a high efficacy and it is recommended for clinical application.
About the Authors
A. V. Snegovoy
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
L. V. Manzyuk
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. J Nat Clin Pract Oncol 2008;5(1):32–43.
2. Трифонов Е.В. Психофизиология человека. Русско-англо-русская энциклопедия; 13-е изд., 2009 г. (www.tryphonov.ru)
3. MASCC Guidelines Antiemetics, 2010.
4. Gralla R. Current trends in the management of chemotherapy-induced emesis. Conference Supportive care in oncology, February 27–28, 2009.
5. Hesketh P.J. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008;358(23):2482–94.
6. Herrstedt J. Antiemetics: state of the art. 34 ESMO–15 ECCO conference. Berlin, 2009; p. 439–41.
7. Dicato M. Medical management of cancer treatment induced emesis. London, 1998.
8. Снеговой А.В. Материалы 1-го Евразийского семинара по поддерживающей терапии в онкологии. Екатеринбург, 2009.
Review
For citations:
Snegovoy A.V., Manzyuk L.V. Role of ganaton in antiemetic therapy. New treatment capacities. Tumors of female reproductive system. 2010;(4):49-53. (In Russ.) https://doi.org/10.17650/1994-4098-2010-0-4-49-53
Views:
644
Email this article 